VectivBio Grabs Tail Of Comet Therapeutics In New Rare Disease Play

Deal Snapshot: VectivBio is expanding its existing focus on rare diseases into inherited metabolic disorders, which affect about one in 800 live births and cause significant mortality in infants and young people.

Business teamwork puzzle pieces.
• Source: Shutterstock

Who: VectivBio Holding AG and Comet Therapeutics Inc.

What: On 31 August, Basel, Switzerland-based VectivBio said it would acquire Cambridge, MA-based Comet, a company focused on developing small molecule drugs for inherited metabolic

More from Deals

More from Business